It has been widely known that tuberculosis treatment might cause mild to severe side effects. One of which is hepatotoxic effect, that might potentially serious and might cause acute liver failure. Hepatoxicity incidence in worldwide has reached 48% in many countries. One of the responsible factor contributing to this is genetical variation on drug metabolizing enzyme for antituberculosis, including GSTM1. Unfortunately, there's no enough evidence regarding distribution of GSTM1 deletion in Indonesia. Meanwhile, the proportion of GSTM1 null in many countries werevaries, reached 43-46%. This study aimed to identify the deletion of GSTM1 on tuberculosis patient receiving antituberculosis. GSTM1 deletion identification was conducted using PCR techniques. The proportion of GSTM1 null genotype in this study was 71.4%.